Multicentre	O
RCT	O
and	O
economic	O
evaluation	O
of	O
a	O
psychological	O
intervention	O
together	O
with	O
a	O
leaflet	O
to	O
reduce	O
risk	O
behaviour	O
amongst	O
men	B-OG
who	O
have	O
sex	O
with	O
men	B-OG
(	O
MSM	O
)	O
prescribed	O
post	O
-	O
exposure	O
prophylaxis	O
for	O
HIV	B-OG
following	O
sexual	O
exposure	O
(	O
PEPSE	O
):	O
A	O
protocol	O

Background	O

Post	O
-	O
exposure	O
prophylaxis	O
(	O
PEP	O
)	O
following	O
sexual	O
exposure	O
to	O
HIV	B-OG
has	O
been	O
recommended	O
as	O
a	O
method	O
of	O
preventing	O
HIV	B-DS
infection	I-DS
in	O
the	O
UK	O
.	O

Men	B-OG
who	O
have	O
sex	O
with	O
men	B-OG
(	O
MSM	O
)	O
are	O
the	O
group	O
most	O
affected	O
by	O
HIV	B-OG
in	O
the	O
UK	O
and	O
their	O
sexual	O
risk	O
taking	O
behaviour	O
is	O
reported	O
to	O
be	O
increasing	O
.	O

One	O
-	O
to	O
-	O
one	O
behavioural	O
interventions	O
,	O
such	O
as	O
motivational	O
interviewing	O
(	O
MI	O
)	O
have	O
been	O
recommended	O
to	O
reduce	O
HIV	B-OG
in	O
high	O
risk	O
groups	O
.	O

The	O
Information	O
,	O
Motivation	O
and	O
Behavioral	O
skills	O
(	O
IMB	O
)	O
model	O
has	O
been	O
shown	O
to	O
provide	O
a	O
good	O
basis	O
for	O
understanding	O
and	O
predicting	O
HIV	B-OG
-	O
relevant	O
health	O
behaviour	O
and	O
health	O
behaviour	O
change	O
,	O
however	O
the	O
IMB	O
has	O
yet	O
to	O
be	O
applied	O
to	O
PEP	O
after	O
risky	O
sexual	O
exposure	O
.	O

The	O
primary	O
aim	O
of	O
this	O
trial	O
is	O
to	O
examine	O
the	O
impact	O
of	O
MI	O
augmented	O
with	O
information	O
provision	O
and	O
behavioural	O
skills	O
building	O
(	O
informed	O
by	O
the	O
IMB	O
Model	O
),	O
over	O
and	O
above	O
usual	O
care	O
,	O
on	O
risky	O
sexual	O
behaviour	O
in	O
MSM	O
prescribed	O
PEP	O
after	O
potential	O
sexual	O
exposure	O
.	O

A	O
secondary	O
aim	O
of	O
this	O
research	O
is	O
to	O
examine	O
the	O
impact	O
of	O
the	O
intervention	O
on	O
adherence	O
to	O
PEP	O
.	O

This	O
study	O
will	O
also	O
provide	O
estimates	O
of	O
the	O
cost	O
-	O
effectiveness	O
of	O
the	O
intervention	O
.	O

Methods	O

A	O
manualised	O
parallel	O
group	O
randomised	O
controlled	O
trial	O
with	O
economic	O
evaluation	O
will	O
be	O
conducted	O
.	O

The	O
primary	O
outcome	O
is	O
the	O
proportion	O
of	O
risky	O
sexual	O
practices	O
.	O

Secondary	O
outcomes	O
include	O
:	O
i	O
)	O
Levels	O
of	O
adherence	O
to	O
PEP	O
treatment	O
;	O
ii	O
)	O
Number	O
of	O
subsequent	O
courses	O
of	O
PEP	O
;	O
iii	O
)	O
Levels	O
of	O
motivation	O
to	O
avoid	O
risky	O
sexual	O
behaviours	O
;	O
iv	O
)	O
Levels	O
of	O
HIV	B-OG
risk	O
-	O
reduction	O
information	O
/	O
knowledge	O
;	O
v	O
)	O
Levels	O
of	O
risk	O
reduction	O
behavioural	O
skills	O
;	O
vi	O
)	O
Diagnosis	O
of	O
anal	B-DS
gonorrhoea	I-DS
,	O
Chlamydia	B-OG
and	O
/	O
or	O
HIV	B-OG
.	O

250	O
participants	O
will	O
be	O
asked	O
to	O
self	O
-	O
complete	O
a	O
questionnaire	O
at	O
four	O
time	O
points	O
during	O
the	O
study	O
(	O
at	O
0	O
,	O
3	O
,	O
6	O
,	O
12	O
months	O
).	O

The	O
intervention	O
will	O
consist	O
of	O
a	O
two	O
-	O
session	O
,	O
fixed	O
duration	O
,	O
telephone	O
administered	O
augmented	O
MI	O
intervention	O
based	O
on	O
the	O
IMB	O
model	O
.	O

A	O
newly	O
developed	O
treatment	O
manual	O
will	O
guide	O
the	O
selection	O
of	O
persuasive	O
communication	O
strategies	O
as	O
appropriate	O
for	O
each	O
participant	O
and	O
will	O
be	O
based	O
on	O
underlying	O
change	O
mechanisms	O
specified	O
by	O
the	O
IMB	O
theoretical	O
framework	O
.	O

Information	O
provision	O
and	O
skills	O
building	O
will	O
also	O
be	O
included	O
in	O
the	O
intervention	O
package	O
through	O
the	O
use	O
of	O
information	O
leaflets	O
and	O
tailored	O
action	O
plans	O
.	O

Fidelity	O
of	O
intervention	O
delivery	O
will	O
be	O
assessed	O
.	O

Discussion	O

The	O
results	O
from	O
this	O
NIHR	O
funded	O
study	O
will	O
identify	O
whether	O
it	O
is	O
appropriate	O
and	O
cost	O
-	O
effective	O
to	O
intervene	O
using	O
one	O
-	O
to	O
-	O
one	O
telephone	O
calls	O
with	O
MSM	O
seeking	O
PEP	O
.	O

If	O
the	O
intervention	O
is	O
effective	O
,	O
further	O
work	O
will	O
be	O
needed	O
on	O
training	O
staff	O
to	O
deliver	O
the	O
intervention	O
competently	O
.	O

Trial	O
registration	O
numbers	O

UKCRN	O
ID	O
:	O
11436	O
;	O
ISRCTN00746242	O
.	O

Background	O

The	O
prevalence	O
of	O
HIV	B-DS
infections	I-DS
continue	O
to	O
rise	O
in	O
the	O
UK	O
,	O
particularly	O
amongst	O
MSM	O
and	O
the	O
reduction	O
of	O
new	O
infections	B-DS
is	O
a	O
key	O
component	O
of	O
the	O
National	O
Strategy	O
for	O
Sexual	O
Health	O
and	O
HIV	B-OG
[	O
1	O
].	O

Recent	O
reports	O
on	O
sexual	O
health	O
highlight	O
the	O
need	O
to	O
invest	O
more	O
in	O
HIV	B-OG
prevention	O
strategies	O
[	O
2	O
,	O
3	O
].	O

The	O
Community	O
HIV	B-OG
and	O
AIDS	B-DS
prevention	O
(	O
CHAPS	O
)	O
policy	O
(	O
led	O
by	O
the	O
Terrence	O
Higgins	O
Trust	O
)	O
identifies	O
post	O
-	O
exposure	O
prophylaxis	O
following	O
sexual	O
exposure	O
(	O
PEPSE	O
)	O
to	O
the	O
human	B-OG
immunodeficiency	I-OG
virus	I-OG
(	O
HIV	B-OG
)	O
as	O
one	O
method	O
of	O
preventing	O
HIV	B-DS
infection	I-DS
in	O
the	O
UK	O
[	O
4	O
].	O

Recommendations	O
for	O
treatment	O
are	O
derived	O
from	O
the	O
existing	O
use	O
of	O
antiretrovirals	O
to	O
prevent	O
HIV	B-DS
infection	I-DS
after	O
high	O
risk	O
occupational	O
exposure	O
to	O
the	O
virus	B-OG
('	O
needle	O
-	O
stick	O
injuries	O
')	O
[	O
5	O
].	O

Recommendations	O
for	O
prescribing	O
PEP	O
result	O
from	O
the	O
clinician	O
'	O
s	O
assessment	O
of	O
risk	O
of	O
transmission	O
.	O

If	O
the	O
risk	O
of	O
HIV	B-OG
transmission	O
through	O
particular	O
sexual	O
practices	O
(	O
such	O
as	O
unprotected	O
anal	O
intercourse	O
)	O
is	O
of	O
a	O
similar	O
magnitude	O
as	O
occupational	O
exposures	O
then	O
PEP	O
should	O
be	O
recommended	O
[	O
6	O
].	O

Evidence	O
suggests	O
that	O
PEP	O
may	O
reduce	O
the	O
risk	O
of	O
HIV	B-DS
infection	I-DS
if	O
given	O
within	O
72	O
hours	O
and	O
adhered	O
to	O
rigorously	O
for	O
28	O
days	O
[	O
5	O
,	O
7	O
,	O
8	O
].	O

Sustained	O
adherence	O
is	O
required	O
to	O
prevent	O
treatment	O
failure	O
,	O
however	O
,	O
non	O
-	O
adherence	O
of	O
a	O
quarter	O
to	O
a	O
third	O
of	O
those	O
prescribed	O
PEP	O
has	O
been	O
reported	O
[	O
9	O
,	O
10	O
].	O

The	O
treatment	O
can	O
be	O
challenging	O
to	O
patients	O
due	O
to	O
side	O
-	O
effects	O
such	O
as	O
diarrhoea	O
,	O
nausea	O
,	O
headaches	O
and	O
vomiting	O
.	O

The	O
treatment	O
is	O
also	O
costly	O
.	O

Men	B-OG
who	O
have	O
sex	O
with	O
men	B-OG
(	O
MSM	O
)	O
are	O
the	O
group	O
most	O
affected	O
by	O
the	O
HIV	B-OG
epidemic	O
in	O
the	O
UK	O
[	O
11	O
]	O
and	O
their	O
sexual	O
risk	O
taking	O
behaviour	O
is	O
reported	O
to	O
be	O
increasing	O
[	O
12	O
,	O
13	O
].	O

As	O
part	O
of	O
a	O
comprehensive	O
strategy	O
across	O
HIV	B-OG
prevention	O
and	O
care	O
,	O
behavioural	O
interventions	O
remain	O
an	O
important	O
tool	O
in	O
the	O
global	O
fight	O
against	O
HIV	B-OG
[	O
14	O
].	O

One	O
-	O
to	O
-	O
one	O
behavioural	O
interventions	O
,	O
such	O
as	O
motivational	O
interviewing	O
(	O
MI	O
)	O
have	O
been	O
recommended	O
[	O
15	O
,	O
16	O
]	O
to	O
reduce	O
HIV	B-OG
in	O
high	O
risk	O
groups	O
.	O

NICE	O
guidance	O
places	O
recommendations	O
for	O
one	O
-	O
to	O
-	O
one	O
interventions	O
within	O
the	O
context	O
of	O
current	O
STI	B-DS
/	O
HIV	B-OG
service	O
provision	O
[	O
1	O
,	O
17	O
]	O
and	O
states	O
that	O
these	O
interventions	O
are	O
integral	O
to	O
the	O
modernisation	O
of	O
sexual	O
health	O
services	O
[	O
16	O
].	O

Seeking	O
PEP	O
after	O
potential	O
sexual	O
exposure	O
may	O
indicate	O
an	O
unmet	O
prevention	O
need	O
and	O
provides	O
an	O
opportunity	O
to	O
target	O
interventions	O
thus	O
potentially	O
lowering	O
the	O
likelihood	O
of	O
further	O
risk	O
behaviour	O
[	O
18	O
,	O
19	O
].	O

We	O
will	O
implement	O
a	O
telephone	O
-	O
administered	O
intervention	O
based	O
on	O
motivational	O
interviewing	O
(	O
MI	O
)	O
augmented	O
with	O
information	O
and	O
behavioural	O
skills	O
building	O
(	O
informed	O
by	O
the	O
Information	O
-	O
Motivation	O
-	O
Behavioral	O
Skills	O
Model	O
).	O

MI	O
is	O
defined	O
as	O
a	O
'	O
directive	O
,	O
client	O
-	O
centred	O
counselling	O
style	O
for	O
eliciting	O
behaviour	O
change	O
by	O
helping	O
clients	O
to	O
explore	O
and	O
resolve	O
ambivalence	O
'	O
[	O
20	O
].	O

It	O
is	O
may	O
be	O
especially	O
effective	O
for	O
individuals	O
who	O
are	O
reluctant	O
to	O
change	O
or	O
who	O
are	O
ambivalent	O
about	O
changing	O
their	O
behaviour	O
and	O
may	O
be	O
particularly	O
appropriate	O
for	O
MSM	O
who	O
may	O
require	O
a	O
more	O
tailored	O
preventive	O
strategy	O
.	O

A	O
systematic	O
review	O
and	O
meta	O
-	O
analysis	O
of	O
RCTs	O
shows	O
that	O
MI	O
outperforms	O
traditional	O
advice	O
giving	O
in	O
the	O
treatment	O
of	O
a	O
range	O
of	O
behavioural	B-DS
problems	I-DS
and	O
diseases	O
[	O
21	O
].	O

More	O
recently	O
,	O
a	O
pilot	O
study	O
has	O
shown	O
the	O
effectiveness	O
of	O
telephone	O
administered	O
MI	O
to	O
reduce	O
risky	O
sexual	O
behaviour	O
in	O
HIV	B-OG
infected	O
rural	O
populations	O
[	O
22	O
].	O

The	O
study	O
will	O
examine	O
whether	O
a	O
two	O
-	O
session	O
,	O
telephone	O
administered	O
augmented	O
motivational	O
interviewing	O
intervention	O
based	O
on	O
the	O
IMB	O
model	O
(	O
Figure	O
1	O
)	O
reduces	O
risky	O
sexual	O
behaviour	O
(	O
compared	O
with	O
'	O
treatment	O
as	O
usual	O
'),	O
in	O
MSM	O
prescribed	O
PEP	O
treatment	O
after	O
potential	O
sexual	O
exposure	O
to	O
HIV	B-OG
.	O

Evidence	O
suggests	O
that	O
the	O
Information	O
-	O
Motivation	O
-	O
Behavioral	O
Skills	O
(	O
IMB	O
)	O
approach	O
could	O
be	O
used	O
to	O
explain	O
sexual	O
risk	O
taking	O
behaviour	O
[	O
23	O
].	O

Moreover	O
,	O
the	O
IMB	O
model	O
has	O
been	O
shown	O
to	O
provide	O
a	O
good	O
basis	O
for	O
understanding	O
and	O
predicting	O
HIV	B-OG
-	O
relevant	O
health	O
behaviour	O
and	O
health	O
behaviour	O
change	O
in	O
almost	O
two	O
decades	O
of	O
research	O
[	O
24	O
].	O

This	O
model	O
further	O
proposes	O
that	O
information	O
relevant	O
to	O
the	O
personal	O
practice	O
of	O
preventive	O
behaviour	O
,	O
motivation	O
to	O
practice	O
prevention	O
and	O
behavioural	O
skills	O
for	O
practicing	O
prevention	O
effectively	O
,	O
are	O
fundamental	O
determinants	O
of	O
HIV	B-OG
/	O
STI	B-DS
preventive	O
behaviour	O
[	O
25	O
].	O

The	O
IMB	O
model	O
proposes	O
an	O
intervention	O
development	O
process	O
involving	O
(	O
1	O
)	O
elicitation	O
of	O
client	O
resources	O
and	O
needs	O
and	O
,	O
(	O
2	O
)	O
matching	O
intervention	O
content	O
to	O
existing	O
need	O
and	O
behaviour	O
change	O
objectives	O
,	O
(	O
3	O
)	O
implementation	O
of	O
information	O
,	O
motivation	O
and	O
skill	O
development	O
techniques	O
interventions	O
according	O
to	O
protocol	O
and	O
,	O
finally	O
,	O
(	O
4	O
)	O
evaluation	O
.	O

The	O
Information	O
-	O
Motivation	O
-	O
Behavioral	O
Skills	O
Model	O
(	O
Fisher	O
and	O
Fisher	O
,	O
1992	O
).	O

Interventions	O
based	O
on	O
this	O
approach	O
has	O
been	O
found	O
to	O
be	O
effective	O
in	O
changing	O
risky	O
sexual	O
behaviour	O
among	O
HIV	B-OG
negative	O
and	O
infected	O
individuals	O
in	O
more	O
than	O
25	O
studies	O
[	O
26	O
]	O
and	O
in	O
changing	O
levels	O
of	O
adherence	O
behaviour	O
amongst	O
people	O
with	O
HIV	B-OG
/	O
AIDS	B-DS
[	O
27	O
,	O
28	O
].	O

The	O
IMB	O
has	O
yet	O
to	O
be	O
applied	O
to	O
a	O
short	O
term	O
prophylactic	O
regimen	O
of	O
medication	O
after	O
risky	O
sexual	O
exposure	O
but	O
its	O
previous	O
successful	O
application	O
to	O
HIV	B-OG
risk	O
reduction	O
suggests	O
that	O
it	O
is	O
an	O
appropriate	O
model	O
on	O
which	O
to	O
base	O
an	O
intervention	O
for	O
those	O
prescribed	O
PEP	O
.	O

This	O
study	O
will	O
also	O
provide	O
estimates	O
of	O
the	O
cost	O
-	O
effectiveness	O
of	O
the	O
intervention	O
through	O
the	O
inclusion	O
of	O
an	O
economic	O
evaluation	O
.	O

Objectives	O
and	O
hypotheses	O

The	O
primary	O
aim	O
is	O
to	O
examine	O
the	O
impact	O
of	O
motivational	O
interviewing	O
augmented	O
with	O
information	O
and	O
behavioural	O
skills	O
building	O
(	O
informed	O
by	O
the	O
Information	O
-	O
Motivation	O
-	O
Behavioral	O
Skills	O
Model	O
),	O
over	O
and	O
above	O
usual	O
care	O
,	O
on	O
risky	O
sexual	O
behaviour	O
in	O
MSM	O
prescribed	O
PEP	O
after	O
potential	O
sexual	O
exposure	O
.	O

A	O
secondary	O
aim	O
of	O
this	O
research	O
is	O
to	O
examine	O
the	O
impact	O
of	O
the	O
intervention	O
on	O
adherence	O
to	O
PEP	O
.	O

Specifically	O
we	O
hypothesize	O
that	O
compared	O
with	O
treatment	O
as	O
usual	O
,	O
those	O
in	O
the	O
intervention	O
arm	O
will	O
:	O

1	O
)	O
Report	O
a	O
reduction	O
in	O
the	O
proportion	O
of	O
risky	O
sexual	O
practices	O
(	O
less	O
unprotected	O
anal	O
intercourse	O
(	O
UAI	O
)	O
(	O
receptive	O
and	O
insertive	O
),	O
increased	O
use	O
of	O
condoms	O
,	O
a	O
reduction	O
in	O
partners	O
);	O

2	O
)	O
Have	O
greater	O
levels	O
of	O
adherence	O
to	O
PEP	O
treatment	O
;	O

3	O
)	O
Have	O
lower	O
rates	O
of	O
subsequent	O
requests	O
for	O
PEP	O
;	O

4	O
)	O
Have	O
lower	O
incidences	O
of	O
HIV	B-OG
.	O

5	O
)	O
Have	O
lower	O
incidences	O
of	O
anal	B-DS
gonorrhoea	I-DS
and	O
Chlamydia	B-OG
;	O

6	O
)	O
Have	O
greater	O
motivation	O
to	O
avoid	O
risky	O
sexual	O
behaviours	O
;	O

7	O
)	O
Have	O
greater	O
knowledge	O
of	O
risk	O
reduction	O
strategies	O
;	O

8	O
)	O
Have	O
greater	O
risk	O
reduction	O
behavioural	O
skills	O
.	O

Methods	O

Study	O
design	O

Parallel	O
group	O
randomised	O
controlled	O
trial	O
(	O
Figure	O
2	O
).	O

CONSORT	O
flowchart	O
of	O
study	O
participants	O
.	O

Participants	O

Eligibility	O
criteria	O

Participants	O
will	O
be	O
MSM	O
,	O
aged	O
≥	O
16	O
years	O
,	O
prescribed	O
PEP	O
after	O
sexual	O
exposure	O
,	O
attending	O
a	O
Genito	O
-	O
urinary	O
Medicine	O
(	O
GUM	O
)	O
clinic	O
that	O
are	O
willing	O
and	O
able	O
to	O
give	O
written	O
,	O
informed	O
consent	O
.	O

Exclusion	O
criteria	O

The	O
following	O
groups	O
of	O
patients	O
will	O
be	O
excluded	O
:	O
people	O
who	O
have	O
received	O
previous	O
psychological	O
support	O
from	O
a	O
clinical	O
psychologist	O
in	O
relation	O
to	O
their	O
sexual	O
risk	O
taking	O
;	O
people	O
with	O
learning	O
difficulties	O
;	O
or	O
those	O
unable	O
to	O
read	O
study	O
materials	O
;	O
or	O
with	O
no	O
means	O
of	O
communication	O
acceptable	O
to	O
the	O
patient	O
;	O
or	O
who	O
are	O
seeking	O
PEP	O
after	O
sexual	B-DS
assault	I-DS
.	O

Recruitment	O
procedure	O

The	O
data	O
collection	O
plan	O
is	O
tailored	O
to	O
the	O
standard	O
patient	O
care	O
protocols	O
stipulated	O
in	O
the	O
BASHH	O
guidelines	O
for	O
PEP	O
[	O
4	O
],	O
and	O
the	O
clinical	O
processes	O
in	O
use	O
at	O
the	O
recruitment	O
sites	O
.	O

PEP	O
is	O
available	O
from	O
GUM	O
or	O
Accident	O
&	O
Emergency	O
(	O
A	O
&	O
E	O
)	O
Departments	O
.	O

Patients	O
are	O
routinely	O
prescribed	O
a	O
5	O
-	O
day	O
course	O
of	O
PEP	O
medication	O
at	O
general	O
GUM	O
clinics	O
,	O
or	O
at	O
A	O
&	O
E	O
departments	O
outside	O
of	O
GUM	O
hours	O
.	O

Whichever	O
mode	O
of	O
access	O
,	O
all	O
patients	O
attend	O
a	O
dedicated	O
PEP	O
clinic	O
at	O
GUM	O
within	O
5	O
days	O
of	O
initial	O
prescription	O
.	O

Recruiting	O
at	O
the	O
GUM	O
clinic	O
will	O
ensure	O
all	O
patients	O
who	O
are	O
prescribed	O
the	O
full	O
course	O
of	O
PEP	O
(	O
28	O
days	O
)	O
are	O
included	O
in	O
the	O
trial	O
from	O
either	O
access	O
route	O
.	O

Eligible	O
participants	O
will	O
be	O
identified	O
by	O
a	O
research	O
nurse	O
/	O
health	O
advisor	O
at	O
the	O
GUM	O
clinic	O
and	O
given	O
study	O
information	O
and	O
consent	O
forms	O
.	O

Participants	O
have	O
a	O
two	O
-	O
week	O
time	O
period	O
in	O
which	O
to	O
consent	O
and	O
return	O
baseline	O
measures	O
.	O

This	O
two	O
week	O
period	O
allows	O
the	O
recruitment	O
of	O
patients	O
at	O
an	O
early	O
stage	O
in	O
their	O
prescription	O
,	O
but	O
at	O
a	O
time	O
when	O
their	O
immediate	O
anxiety	B-DS
should	O
be	O
reduced	O
and	O
they	O
are	O
able	O
to	O
give	O
considered	O
,	O
informed	O
consent	O
.	O

Baseline	O
and	O
follow	O
-	O
up	O
assessments	O

Participants	O
enrolled	O
into	O
the	O
study	O
will	O
be	O
asked	O
to	O
self	O
-	O
complete	O
a	O
questionnaire	O
at	O
four	O
time	O
points	O
during	O
the	O
study	O
(	O
at	O
0	O
,	O
3	O
,	O
6	O
,	O
12	O
months	O
).	O

The	O
baseline	O
questionnaire	O
will	O
be	O
administered	O
at	O
the	O
recruitment	O
stage	O
.	O

Upon	O
receiving	O
the	O
consent	O
forms	O
and	O
baseline	O
assessments	O
,	O
participants	O
will	O
be	O
randomly	O
allocated	O
to	O
either	O
intervention	O
or	O
control	O
conditions	O
(	O
see	O
randomisation	O
section	O
).	O

The	O
second	O
questionnaire	O
will	O
be	O
either	O
posted	O
to	O
patients	O
,	O
accessed	O
via	O
an	O
email	O
link	O
or	O
the	O
internet	O
(	O
as	O
per	O
consent	O
)	O
prior	O
to	O
their	O
3	O
-	O
month	O
follow	O
-	O
up	O
appointment	O
with	O
the	O
clinic	O
.	O

Any	O
patients	O
who	O
have	O
not	O
returned	O
completed	O
questionnaires	O
before	O
their	O
'	O
3	O
-	O
month	O
'	O
follow	O
-	O
up	O
will	O
be	O
sent	O
repeat	O
copies1	O
(	O
as	O
per	O
consent	O
),	O
and	O
subsequently	O
called	O
on	O
the	O
telephone	O
(	O
if	O
consented	O
),	O
and	O
finally	O
,	O
may	O
be	O
approached	O
by	O
study	O
staff	O
at	O
their	O
clinic	O
appointment	O
.	O

The	O
third	O
and	O
fourth	O
questionnaires	O
will	O
be	O
posted	O
to	O
patients	O
or	O
accessed	O
via	O
an	O
email	O
link	O
or	O
the	O
internet	O
6	O
and	O
12	O
months	O
after	O
the	O
end	O
of	O
PEP	O
.	O

Repeat	O
copies	O
,	O
and	O
subsequent	O
telephone	O
calls	O
/	O
text	O
messages	O
,	O
will	O
be	O
used	O
as	O
reminders	O
.	O

The	O
recruitment	O
period	O
is	O
for	O
12	O
months	O
to	O
allow	O
sufficient	O
numbers	O
of	O
participants	O
to	O
be	O
recruited	O
.	O

A	O
sample	O
size	O
of	O
250	O
(	O
allowing	O
for	O
a	O
75	O
%	O
recruitment	O
rate	O
and	O
50	O
%	O
retention	O
rate	O
)	O
is	O
achievable	O
within	O
the	O
time	O
-	O
frame	O
from	O
four	O
sites	O
and	O
we	O
anticipate	O
that	O
numbers	O
will	O
be	O
higher	O
given	O
the	O
increasing	O
trends	O
for	O
PEP	O
requests	O
.	O

Randomization	O
and	O
blinding	O

Participants	O
will	O
be	O
randomised	O
after	O
consent	O
and	O
collection	O
of	O
baseline	O
measures	O
.	O

The	O
recruiting	O
staff	O
will	O
not	O
have	O
access	O
to	O
the	O
results	O
of	O
randomisation	O
prior	O
to	O
recruiting	O
the	O
participant	O
.	O

Randomisation	O
will	O
occur	O
within	O
each	O
clinic	O
.	O

The	O
allocation	O
sequence	O
will	O
be	O
generated	O
and	O
released	O
to	O
the	O
interventionist	O
on	O
a	O
case	O
-	O
by	O
-	O
case	O
basis	O
by	O
an	O
independent	O
company	O
who	O
specialise	O
in	O
supplying	O
random	O
generated	O
sequences	O
for	O
research	O
.	O

The	O
randomisation	O
sequence	O
will	O
be	O
recorded	O
.	O

This	O
is	O
a	O
single	O
-	O
blind	O
trial	O
,	O
given	O
the	O
nature	O
of	O
the	O
behavioural	O
intervention	O
,	O
blinding	O
of	O
participants	O
is	O
not	O
feasible	O
and	O
the	O
interventionist	O
will	O
know	O
that	O
all	O
those	O
contacted	O
are	O
in	O
the	O
intervention	O
arm	O
.	O

The	O
statistician	O
will	O
be	O
blind	O
to	O
individual	O
results	O
during	O
the	O
trial	O
and	O
the	O
allocation	O
-	O
to	O
-	O
trial	O
-	O
arm	O
coding	O
will	O
be	O
revealed	O
when	O
the	O
dataset	O
is	O
sealed	O
.	O

The	O
interventionist	O
and	O
supervisors	O
will	O
be	O
blind	O
to	O
the	O
baseline	O
and	O
follow	O
-	O
up	O
measures	O
which	O
will	O
not	O
be	O
involved	O
in	O
the	O
delivery	O
of	O
the	O
intervention	O
.	O

Anonymised	O
responses	O
will	O
be	O
entered	O
onto	O
the	O
database	O
by	O
a	O
person	O
unconnected	O
to	O
the	O
project	O
.	O

Trial	O
treatment	O
arms	O

Control	O
group	O
:	O
Treatment	O
as	O
usual	O

Both	O
of	O
the	O
groups	O
will	O
receive	O
'	O
treatment	O
as	O
usual	O
':	O
Patients	O
are	O
initially	O
seen	O
by	O
a	O
HA	O
/	O
SpN	O
for	O
an	O
initial	O
consultation	O
,	O
5	O
day	O
prescription	O
of	O
PEP	O
and	O
blood	O
tests	O
(	O
for	O
HIV	B-OG
,	O
Hepatitis	B-DS
B	I-DS
and	O
liver	O
function	O
).	O

Patients	O
receive	O
their	O
first	O
follow	O
-	O
up	O
appointment	O
5	O
days	O
later	O
to	O
receive	O
further	O
PEP	O
(	O
if	O
HIV	B-OG
-	O
ve	O
).	O

After	O
the	O
28	O
day	O
treatment	O
regimen	O
patients	O
receive	O
either	O
a	O
face	O
-	O
to	O
-	O
face	O
or	O
telephone	O
appointment	O
with	O
the	O
HA	O
/	O
SpN	O
to	O
discuss	O
their	O
sexual	O
health	O
,	O
adherence	O
to	O
PEP	O
and	O
the	O
blood	O
test	O
results	O
.	O

At	O
4	O
months	O
after	O
exposure	O
(	O
3	O
months	O
after	O
the	O
end	O
of	O
PEP	O
)	O
patients	O
are	O
recalled	O
by	O
the	O
HA	O
for	O
HIV	B-OG
testing	O
.	O

In	O
order	O
to	O
assess	O
the	O
impact	O
of	O
the	O
intervention	O
on	O
outcome	O
measures	O
and	O
IMB	O
constructs	O
,	O
those	O
allocated	O
to	O
the	O
control	O
group	O
will	O
be	O
asked	O
to	O
complete	O
all	O
measures	O
at	O
0	O
,	O
3	O
,	O
6	O
,	O
and	O
12	O
months	O
.	O

Intervention	O
group	O

Procedure	O

The	O
intervention	O
group	O
will	O
receive	O
'	O
treatment	O
as	O
usual	O
'	O
plus	O
the	O
addition	O
of	O
an	O
intervention	O
which	O
will	O
be	O
delivered	O
as	O
two	O
telephone	O
sessions	O
employing	O
motivational	O
interviewing	O
(	O
MI	O
)	O
augmented	O
with	O
information	O
and	O
skills	O
building	O
based	O
on	O
the	O
IMB	O
model	O
of	O
behaviour	O
change	O
.	O

The	O
first	O
telephone	O
call	O
will	O
be	O
made	O
within	O
one	O
week	O
of	O
the	O
participant	O
being	O
consented	O
into	O
the	O
trial	O
and	O
after	O
baseline	O
assessments	O
are	O
received	O
.	O

The	O
second	O
call	O
will	O
occur	O
7	O
days	O
(+/-	O
2	O
days	O
)	O
later	O
.	O

The	O
intervention	O
will	O
be	O
completed	O
by	O
the	O
end	O
of	O
the	O
28	O
day	O
course	O
of	O
PEP	O
.	O

A	O
telephone	O
format	O
is	O
proposed	O
to	O
allow	O
the	O
same	O
person	O
to	O
conduct	O
all	O
interventional	O
sessions	O
to	O
control	O
for	O
provider	O
differences	O
and	O
to	O
facilitate	O
recruitment	O
from	O
a	O
wide	O
geographical	O
area	O
in	O
an	O
economical	O
manner	O
.	O

If	O
shown	O
to	O
be	O
effective	O
,	O
this	O
intervention	O
would	O
be	O
sustainable	O
as	O
an	O
improvement	O
to	O
the	O
routine	O
care	O
model	O
.	O

Duration	O
and	O
content	O
of	O
intervention	O

Telephone	O
delivered	O
MI	O

Each	O
telephone	O
session	O
will	O
be	O
a	O
maximum	O
of	O
30	O
minutes	O
long	O
.	O

The	O
second	O
session	O
will	O
contain	O
similar	O
content	O
to	O
the	O
first	O
but	O
will	O
reiterate	O
and	O
build	O
on	O
the	O
risk	O
reduction	O
motivation	O
from	O
session	O
1	O
.	O

In	O
the	O
case	O
of	O
drop	O
-	O
out	O
between	O
the	O
2	O
intervention	O
sessions	O
,	O
the	O
dose	O
-	O
response	O
will	O
be	O
assessed	O
.	O

The	O
interventionist	O
will	O
initially	O
assess	O
individual	O
risk	O
behaviours	O
and	O
any	O
informational	O
,	O
motivational	O
or	O
skill	O
deficits	O
which	O
have	O
contributed	O
to	O
maintenance	O
of	O
participants	O
'	O
risky	O
sexual	O
behaviours	O
and	O
discuss	O
particular	O
areas	O
related	O
to	O
risky	O
sex	O
e	O
.	O
g	O
.	O
the	O
use	O
of	O
alcohol	O
or	O
drugs	O
during	O
sex	O
.	O

The	O
interventionist	O
will	O
elicit	O
self	O
-	O
motivational	O
statements	O
from	O
the	O
participant	O
with	O
the	O
use	O
of	O
open	O
-	O
ended	O
questions	O
and	O
will	O
utilise	O
MI	O
strategies	O
to	O
increase	O
motivation	O
to	O
change	O
,	O
including	O
:	O

1	O
)	O
Providing	O
the	O
participant	O
with	O
feedback	O
about	O
his	O
risky	O
sexual	O
behaviours	O

2	O
)	O
Increasing	O
the	O
participant	O
'	O
s	O
sense	O
of	O
responsibility	O
to	O
reduce	O
risky	O
sexual	O
behaviours	O

3	O
)	O
Providing	O
brief	O
and	O
direct	O
advice	O
to	O
create	O
a	O
desire	O
for	O
change	O

4	O
)	O
Providing	O
a	O
menu	O
of	O
options	O
from	O
which	O
the	O
participant	O
can	O
choose	O
to	O
reduce	O
risk	O

5	O
)	O
Demonstrating	O
empathy	O
by	O
listening	O
carefully	O
,	O
and	O
accurately	O
understanding	O
his	O
problems	O

6	O
)	O
Enhancing	O
self	O
-	O
efficacy	O
to	O
reduce	O
risky	O
sexual	O
behaviours	O
[	O
29	O
]	O

If	O
an	O
individual	O
discontinues	O
with	O
PEP	O
before	O
the	O
end	O
of	O
the	O
treatment	O
,	O
they	O
will	O
still	O
be	O
eligible	O
to	O
continue	O
in	O
the	O
study	O
.	O

Data	O
on	O
adherence	O
to	O
PEP	O
will	O
be	O
captured	O
by	O
the	O
measures	O
of	O
adherence	O
and	O
a	O
review	O
of	O
the	O
medical	O
notes	O
.	O

The	O
role	O
of	O
the	O
manual	O

The	O
manual	O
will	O
guide	O
the	O
selection	O
of	O
persuasive	O
communication	O
strategies	O
appropriate	O
for	O
each	O
participant	O
and	O
will	O
be	O
based	O
on	O
underlying	O
change	O
mechanisms	O
specified	O
by	O
the	O
IMB	O
theoretical	O
framework	O
.	O

The	O
manual	O
describes	O
how	O
to	O
elicit	O
information	O
and	O
includes	O
scripts	O
describing	O
likely	O
sexual	O
-	O
risk	O
scenarios	O
.	O

Specific	O
behaviour	O
change	O
techniques	O
are	O
identified	O
[	O
30	O
,	O
31	O
]	O
and	O
possible	O
responses	O
exemplified	O
.	O

Information	O
provision	O
and	O
skills	O
building	O

Information	O
about	O
HIV	B-OG
risk	O
behaviour	O
,	O
prevalence	O
and	O
strategies	O
to	O
minimise	O
risk	O
will	O
be	O
provided	O
to	O
those	O
allocated	O
into	O
the	O
intervention	O
arm	O
('	O
Ready	O
for	O
Action	O
'	O
Second	O
Edition	O
,	O
and	O
'	O
Get	O
it	O
on	O
'	O
condom	O
guide	O
both	O
produced	O
by	O
the	O
Terrence	O
Higgins	O
Trust	O
).	O

This	O
will	O
be	O
either	O
sent	O
by	O
post	O
,	O
email	O
or	O
accessed	O
via	O
the	O
internet	O
(	O
as	O
preferred	O
)	O
after	O
baseline	O
measures	O
have	O
been	O
returned	O
but	O
before	O
the	O
intervention	O
.	O

The	O
interventionist	O
will	O
prompt	O
the	O
participant	O
to	O
read	O
the	O
information	O
if	O
they	O
have	O
not	O
already	O
done	O
so	O
.	O

The	O
skills	O
building	O
component	O
of	O
the	O
intervention	O
will	O
be	O
given	O
during	O
the	O
telephone	O
session	O
in	O
the	O
form	O
of	O
interventionist	O
-	O
provided	O
suggestions	O
of	O
practical	O
strategies	O
needed	O
to	O
master	O
these	O
skills	O
.	O

A	O
well	O
-	O
specified	O
action	O
plan	O
will	O
be	O
developed	O
and	O
agreed	O
on	O
(	O
between	O
interventionist	O
and	O
participant	O
)	O
during	O
the	O
session	O
and	O
the	O
participant	O
will	O
be	O
asked	O
to	O
write	O
this	O
down	O
and	O
enact	O
it	O
.	O

The	O
interventionist	O
will	O
also	O
write	O
down	O
the	O
agreed	O
action	O
plan	O
and	O
send	O
this	O
to	O
the	O
participant	O
after	O
the	O
session	O
(	O
either	O
by	O
post	O
,	O
or	O
email	O
as	O
indicated	O
by	O
participant	O
).	O

Questions	O
about	O
adherence	O
to	O
practicing	O
the	O
action	O
plan	O
are	O
included	O
in	O
the	O
follow	O
-	O
up	O
questionnaires	O
.	O

Treatment	O
fidelity	O

Assessing	O
the	O
fidelity	O
of	O
the	O
treatment	O
is	O
an	O
important	O
component	O
of	O
successful	O
research	O
dissemination	O
.	O

Translating	O
effective	O
behavioural	O
change	O
interventions	O
from	O
this	O
research	O
setting	O
to	O
clinical	O
practice	O
can	O
be	O
facilitated	O
better	O
when	O
treatment	O
fidelity	O
strategies	O
are	O
used	O
as	O
guidelines	O
for	O
implementing	O
new	O
interventions	O
in	O
clinical	O
contexts	O
.	O

In	O
order	O
to	O
monitor	O
the	O
reliability	O
and	O
validity	O
of	O
the	O
intervention	O
,	O
assessment	O
of	O
both	O
the	O
interventionist	O
and	O
the	O
participant	O
will	O
conducted	O
as	O
per	O
National	O
Institutes	O
of	O
Health	O
(	O
NIH	O
)	O
Behaviour	O
Change	O
Consortium	O
'	O
best	O
practice	O
'	O
recommendations	O
.	O

Ensuring	O
same	O
treatment	O
dose	O
within	O
conditions	O
will	O
be	O
ensured	O
by	O
a	O
fixed	O
number	O
of	O
sessions	O
and	O
by	O
delivery	O
within	O
the	O
intervention	O
period	O
.	O

Ensuring	O
interventionist	O
skill	O
acquisition	O
and	O
minimising	O
'	O
drift	O
'	O
in	O
interventionist	O
skills	O
will	O
be	O
minimised	O
by	O
the	O
development	O
and	O
use	O
of	O
a	O
treatment	O
manual	O
;	O
by	O
monitoring	O
and	O
providing	O
feedback	O
to	O
the	O
interventionist	O
;	O
and	O
by	O
providing	O
adequate	O
training	O
.	O

The	O
gold	O
standard	O
method	O
to	O
ensure	O
standard	O
delivery	O
of	O
the	O
intervention	O
is	O
to	O
evaluate	O
or	O
code	O
the	O
sessions	O
(	O
through	O
audiotape	O
)	O
according	O
to	O
predefined	O
criteria	O
.	O

A	O
validated	O
instrument	O
,	O
the	O
Motivational	O
Interviewing	O
Skill	O
Code	O
(	O
MISC	O
)	O
[	O
29	O
],	O
will	O
be	O
used	O
to	O
provide	O
structured	O
feedback	O
,	O
to	O
monitor	O
and	O
document	O
adherence	O
to	O
MI	O
principles	O
during	O
weekly	O
supervision	O
.	O

The	O
interventionist	O
will	O
also	O
be	O
required	O
to	O
complete	O
a	O
process	O
evaluation	O
checklist	O
(	O
adapted	O
from	O
the	O
NHS	O
Health	O
Trainer	O
Handbook	O
[	O
32	O
])	O
after	O
each	O
intervention	O
session	O
to	O
remind	O
him	O
to	O
include	O
the	O
appropriate	O
skills	O
and	O
content	O
for	O
each	O
intervention	O
and	O
minimise	O
bias	O
.	O

The	O
advisory	O
board	O
will	O
be	O
used	O
to	O
monitor	O
whether	O
the	O
treatment	O
protocol	O
has	O
been	O
adhered	O
to	O
during	O
the	O
recruitment	O
and	O
intervention	O
period	O
.	O

Reduction	O
of	O
differences	O
within	O
treatments	O
will	O
be	O
ensured	O
by	O
the	O
use	O
of	O
one	O
trained	O
interventionist	O
.	O

Measures	O

Primary	O
outcome	O

The	O
proportion	O
of	O
risky	O
sexual	O
practices	O
.	O

Risk	O
Behaviour	O
outcome	O
measure	O

A	O
Risk	O
Behaviour	O
outcome	O
measure	O
has	O
been	O
developed	O
to	O
include	O
items	O
of	O
potential	O
HIV	B-OG
transmission	O
-	O
risk	O
sexual	O
behaviour	O
:	O
number	O
of	O
episodes	O
of	O
unprotected	O
anal	O
intercourse	O
(	O
UAI	O
)	O
(	O
receptive	O
and	O
insertive	O
)	O
over	O
a	O
three	O
month	O
time	O
period	O
with	O
individuals	O
of	O
unknown	O
or	O
HIV	B-OG
positive	O
status	O
,	O
consistency	O
of	O
condom	O
use	O
,	O
number	O
of	O
partners	O
using	O
no	O
protection	O
.	O

(	O
Unprotected	O
receptive	O
oral	O
sex	O
with	O
an	O
HIV	B-OG
+	O
ve	O
person	O
is	O
associated	O
with	O
minimal	O
HIV	B-OG
transmission	O
risk	O
and	O
thus	O
is	O
not	O
included	O
).	O

Secondary	O
outcomes	O
(	O
and	O
method	O
of	O
assessment	O
)	O

i	O
)	O
Levels	O
of	O
adherence	O
to	O
PEP	O
treatment	O
(	O
Morisky	O
Medication	O
Adherence	O
Scale	O
(	O
MMAS	O
)	O
[	O
33	O
]	O
adapted	O
for	O
use	O
in	O
PEP	O
).	O

ii	O
)	O
Number	O
of	O
subsequent	O
courses	O
of	O
PEP	O
(	O
self	O
-	O
report	O
and	O
medical	O
record	O
review	O
).	O

iii	O
)	O
Diagnosis	O
of	O
anal	B-DS
gonorrhoea	I-DS
and	O
Chlamydia	B-OG
.	O
2	O

iv	O
)	O
Diagnosis	O
of	O
HIV	B-OG
.	O

v	O
)	O
Levels	O
of	O
motivation	O
to	O
avoid	O
risky	O
sexual	O
behaviours	O
('	O
Measures	O
of	O
Motivation	O
to	O
Perform	O
AIDS	B-DS
Preventive	O
Behavior	O
'	O
questionnaire	O
[	O
34	O
]	O
adapted	O
for	O
use	O
with	O
MSM	O
.	O

This	O
questionnaire	O
provides	O
assessment	O
of	O
attitudes	O
,	O
subjective	O
norms	O
and	O
behavioural	O
intentions	O
in	O
relation	O
to	O
HIV	B-OG
risk	O
-	O
reduction	O
).	O

vi	O
)	O
Levels	O
of	O
HIV	B-OG
risk	O
-	O
reduction	O
information	O
/	O
knowledge	O
('	O
Health	O
and	O
Relationships	O
Survey	O
'	O
[	O
34	O
]	O
adapted	O
for	O
use	O
with	O
MSM	O
.	O

Items	O
are	O
summed	O
to	O
form	O
an	O
HIV	B-OG
prevention	O
information	O
scale	O
score	O
).	O

vii	O
)	O
Levels	O
of	O
risk	O
reduction	O
behavioural	O
skills	O
('	O
Behavioral	O
Skills	O
Measure	O
'	O
[	O
34	O
].	O

This	O
consists	O
of	O
two	O
subscales	O
which	O
assess	O
the	O
perceived	O
difficulty	O
of	O
reducing	O
HIV	B-OG
risk	O
behaviour	O
and	O
the	O
perceived	O
effectiveness	O
of	O
methods	O
to	O
reduce	O
risk	O
).	O

With	O
the	O
exception	O
of	O
adherence	O
,	O
all	O
outcome	O
measures	O
will	O
use	O
a	O
retrospective	O
recall	O
period	O
of	O
'	O
the	O
past	O
3	O
months	O
'.	O

Other	O
factors	O
assessed	O
by	O
self	O
-	O
report	O
questionnaire	O
at	O
each	O
time	O
point	O
will	O
be	O
alcohol	O
and	O
substance	B-DS
use	I-DS
.	O

Socio	O
-	O
demographic	O
(	O
age	O
,	O
ethnicity	O
,	O
education	O
,	O
employment	O
,	O
relationship	O
status	O
)	O
will	O
be	O
assessed	O
at	O
baseline	O
.	O

Experience	O
of	O
treatment	O
side	O
-	O
effects	O
will	O
be	O
assessed	O
using	O
a	O
previously	O
used	O
measure	O
at	O
3	O
month	O
together	O
with	O
the	O
measure	O
of	O
adherence	O
.	O

Frequency	O
and	O
duration	O
of	O
follow	O
-	O
up	O

The	O
primary	O
and	O
secondary	O
outcomes	O
ii	O
,	O
v	O
,	O
vi	O
,	O
and	O
vii	O
will	O
be	O
collected	O
at	O
3	O
,	O
6	O
and	O
12	O
months	O
after	O
the	O
end	O
of	O
treatment	O
(	O
and	O
the	O
end	O
of	O
the	O
intervention	O
).	O

Secondary	O
outcome	O
i	O
.	O
will	O
be	O
collected	O
at	O
3	O
months	O
only	O
.	O

Outcomes	O
iii	O
.	O
and	O
iv	O
.	O
will	O
be	O
collected	O
at	O
12	O
months	O
only	O
.	O

The	O
follow	O
-	O
up	O
period	O
is	O
for	O
12	O
months	O
to	O
determine	O
intervention	O
sustainability	O
.	O

Participants	O
will	O
be	O
contacted	O
by	O
telephone	O
prior	O
to	O
each	O
follow	O
-	O
up	O
assessment	O
to	O
remind	O
them	O
of	O
their	O
participation	O
in	O
the	O
study	O
and	O
to	O
ask	O
their	O
preference	O
for	O
follow	O
-	O
up	O
(	O
postal	O
,	O
email	O
/	O
internet	O
or	O
face	O
-	O
to	O
-	O
face	O
).	O

Analyses	O
plan	O
and	O
power	O
calculation	O

For	O
the	O
analysis	O
of	O
main	O
effects	O
for	O
the	O
primary	O
outcome	O
a	O
mixed	O
-	O
design	O
ANCOVA	O
will	O
be	O
used	O
with	O
one	O
between	O
-	O
groups	O
factor	O
(	O
treatment	O
vs	O
.	O
control	O
)	O
and	O
one	O
within	O
-	O
groups	O
factor	O
(	O
baseline	O
,	O
3	O
-,	O
6	O
-	O
and	O
12	O
-	O
month	O
measures	O
).	O

For	O
this	O
analysis	O
the	O
estimated	O
effect	O
size	O
is	O
f	O
=	O
0	O
.	O
1	O
(	O
based	O
on	O
a	O
moderate	O
estimate	O
of	O
effect	O
size	O
from	O
a	O
meta	O
-	O
analysis	O
[	O
24	O
]	O
of	O
one	O
to	O
one	O
interventions	O
to	O
reduce	O
UAI	O
in	O
MSM	O
).	O

90	O
%	O
power	O
at	O
0	O
.	O
05	O
level	O
of	O
significance	O
requires	O
a	O
sample	O
of	O
250	O
(	O
125	O
in	O
each	O
arm	O
).	O

Secondary	O
outcomes	O
will	O
be	O
analysed	O
for	O
the	O
same	O
effect	O
size	O
but	O
with	O
significance	O
adjusted	O
to	O
0	O
.	O
01	O
and	O
power	O
to	O
80	O
%.	O

Piloting	O

All	O
study	O
materials	O
(	O
measures	O
,	O
training	O
manual	O
,	O
intervention	O
,	O
method	O
for	O
data	O
sharing	O
)	O
will	O
be	O
piloted	O
on	O
a	O
sample	O
of	O
MSM	O
and	O
refined	O
in	O
response	O
to	O
their	O
feedback	O
,	O
together	O
with	O
input	O
from	O
the	O
Advisory	O
Board	O
and	O
Steering	O
Group	O
.	O

Economic	O
evaluation	O

The	O
economic	O
evaluation	O
will	O
compare	O
NHS	O
costs	O
of	O
the	O
intervention	O
with	O
usual	O
care	O
.	O

Health	O
outcomes	O
will	O
be	O
expressed	O
as	O
quality	O
-	O
adjusted	O
life	O
-	O
years	O
(	O
QALYs	O
).	O

Decision	O
modelling	O
techniques	O
will	O
be	O
used	O
to	O
extrapolate	O
the	O
RCT	O
results	O
to	O
predict	O
longer	O
term	O
costs	O
and	O
health	O
outcomes	O
.	O

A	O
single	O
economic	O
model	O
with	O
an	O
appropriate	O
time	O
horizon	O
is	O
proposed	O
based	O
on	O
Bernoulli	O
techniques	O
.	O

This	O
approach	O
has	O
been	O
used	O
in	O
a	O
number	O
of	O
previously	O
published	O
studies	O
[	O
35	O
].	O

This	O
is	O
a	O
conservative	O
approach	O
because	O
it	O
only	O
partially	O
accounts	O
for	O
chains	O
of	O
infections	B-DS
which	O
may	O
be	O
prevented	O
,	O
rather	O
than	O
prevention	O
of	O
single	O
infections	B-DS
.	O

The	O
purpose	O
of	O
the	O
Bernoulli	O
model	O
is	O
to	O
translate	O
changes	O
in	O
sexual	O
behaviour	O
as	O
observed	O
in	O
the	O
trial	O
into	O
the	O
probability	O
of	O
HIV	B-OG
transmission	O
in	O
order	O
to	O
estimate	O
the	O
number	O
of	O
averted	O
transmissions	O
.	O

To	O
inform	O
this	O
model	O
,	O
baseline	O
data	O
will	O
be	O
collected	O
to	O
allow	O
a	O
more	O
complex	O
infectious	B-DS
diseases	I-DS
model	O
to	O
be	O
built	O
if	O
the	O
intervention	O
is	O
proven	O
.	O

The	O
data	O
are	O
likely	O
to	O
be	O
useful	O
for	O
a	O
range	O
of	O
other	O
HIV	B-OG
modelling	O
studies	O
.	O

Intervention	O
costs	O
will	O
be	O
collected	O
contemporaneously	O
.	O

The	O
longer	O
term	O
costs	O
and	O
health	O
effects	O
of	O
HIV	B-DS
infection	I-DS
will	O
be	O
estimated	O
using	O
published	O
evidence	O
since	O
infection	B-DS
-	O
associated	O
sequelae	O
will	O
not	O
occur	O
during	O
the	O
trial	O
period	O
.	O

Future	O
costs	O
and	O
QALYs	O
will	O
be	O
discounted	O
at	O
3	O
.	O
5	O
%	O
per	O
annum	O
.	O

Results	O
will	O
be	O
reported	O
as	O
incremental	O
cost	O
per	O
QALYs	O
and	O
cost	O
-	O
effectiveness	O
acceptability	O
curves	O
.	O

Vulnerable	O
patients	O
and	O
disclosures	O

If	O
during	O
the	O
intervention	O
the	O
patient	O
discloses	O
current	O
harmful	O
thoughts	O
or	O
behaviour	O
towards	O
themselves	O
or	O
another	O
,	O
they	O
will	O
be	O
referred	O
to	O
their	O
treating	O
consultant	O
,	O
GP	O
or	O
psychiatric	O
support	O
provided	O
by	O
the	O
GUM	O
clinic	O
.	O

The	O
breaking	O
of	O
confidentiality	O
under	O
these	O
circumstances	O
is	O
detailed	O
on	O
the	O
consent	O
form	O
.	O

Anonymity	O
and	O
confidentiality	O
of	O
data	O

Participants	O
anonymity	O
will	O
be	O
protected	O
by	O
the	O
allocation	O
of	O
a	O
code	O
(	O
not	O
a	O
clinic	O
or	O
NHS	O
number	O
)	O
for	O
use	O
on	O
the	O
database	O
.	O

Confidentiality	O
and	O
data	O
sharing	O
between	O
participant	O
sites	O

All	O
patient	O
-	O
related	O
information	O
to	O
be	O
shared	O
through	O
encrypted	O
NHS	O
email	O
system	O
.	O

Ethical	O
approval	O

The	O
study	O
protocol	O
was	O
approved	O
by	O
the	O
National	O
Research	O
Ethics	O
Service	O
(	O
NRES	O
)	O
Committee	O
South	O
East	O
Coast	O
-	O
Surrey	O
(	O
ref	O
:	O
11	O
/	O
LO	O
/	O
0718	O
)	O
in	O
2011	O
.	O

Discussion	O

This	O
paper	O
describes	O
the	O
protocol	O
of	O
a	O
randomised	O
controlled	O
trial	O
to	O
evaluate	O
the	O
impact	O
of	O
motivational	O
interviewing	O
augmented	O
with	O
information	O
and	O
behavioural	O
skills	O
building	O
(	O
informed	O
by	O
the	O
Information	O
-	O
Motivation	O
-	O
Behavioural	O
Skills	O
Model	O
),	O
over	O
and	O
above	O
usual	O
care	O
,	O
on	O
risky	O
sexual	O
behaviour	O
in	O
MSM	O
prescribed	O
PEP	O
after	O
potential	O
sexual	O
exposure	O
.	O

A	O
secondary	O
aim	O
of	O
this	O
research	O
is	O
to	O
examine	O
the	O
impact	O
of	O
the	O
intervention	O
on	O
adherence	O
to	O
PEP	O
.	O

This	O
study	O
will	O
also	O
provide	O
estimates	O
of	O
the	O
cost	O
-	O
effectiveness	O
of	O
the	O
intervention	O
through	O
the	O
inclusion	O
of	O
an	O
economic	O
evaluation	O
.	O

One	O
of	O
the	O
strengths	O
of	O
this	O
study	O
is	O
that	O
the	O
intervention	O
is	O
targeting	O
individuals	O
who	O
may	O
be	O
deemed	O
as	O
high	O
risk	O
:	O
those	O
who	O
have	O
presented	O
for	O
PEP	O
treatment	O
after	O
a	O
potential	O
sexual	O
exposure	O
.	O

Men	B-OG
who	O
have	O
sex	O
with	O
men	B-OG
(	O
MSM	O
)	O
are	O
the	O
group	O
most	O
affected	O
by	O
the	O
HIV	B-OG
epidemic	O
in	O
the	O
UK	O
[	O
11	O
]	O
and	O
their	O
sexual	O
risk	O
taking	O
behaviour	O
is	O
reported	O
to	O
be	O
increasing	O
[	O
12	O
,	O
13	O
].	O

As	O
part	O
of	O
a	O
comprehensive	O
strategy	O
across	O
HIV	B-OG
prevention	O
and	O
care	O
,	O
behavioural	O
interventions	O
remain	O
an	O
important	O
tool	O
in	O
the	O
global	O
fight	O
against	O
HIV	B-OG
[	O
14	O
].	O

One	O
-	O
to	O
-	O
one	O
behavioural	O
interventions	O
,	O
such	O
as	O
motivational	O
interviewing	O
(	O
MI	O
)	O
have	O
been	O
recommended	O
[	O
15	O
,	O
16	O
]	O
to	O
reduce	O
HIV	B-OG
in	O
high	O
risk	O
groups	O
.	O

Although	O
the	O
intervention	O
is	O
tailored	O
to	O
the	O
individual	O
,	O
our	O
proposed	O
intervention	O
is	O
manualised	O
so	O
that	O
the	O
content	O
delivered	O
will	O
be	O
similar	O
and	O
based	O
on	O
the	O
principles	O
of	O
MI	O
with	O
the	O
underlying	O
change	O
mechanisms	O
specified	O
by	O
the	O
IMB	O
Model	O
.	O

As	O
part	O
of	O
this	O
study	O
a	O
manual	O
has	O
been	O
developed	O
.	O

Specific	O
behaviour	O
change	O
techniques	O
used	O
will	O
then	O
be	O
able	O
to	O
be	O
identified	O
and	O
quantified	O
.	O

Translating	O
effective	O
behavioural	O
change	O
interventions	O
from	O
the	O
research	O
setting	O
to	O
clinical	O
practice	O
can	O
be	O
facilitated	O
better	O
when	O
treatment	O
fidelity	O
strategies	O
are	O
used	O
as	O
guidelines	O
for	O
implementing	O
new	O
interventions	O
in	O
clinical	O
contexts	O
.	O

We	O
will	O
be	O
monitoring	O
the	O
reliability	O
and	O
validity	O
of	O
the	O
intervention	O
which	O
is	O
an	O
additional	O
strength	O
of	O
the	O
study	O
.	O

A	O
recent	O
review	O
[	O
14	O
]	O
highlighted	O
that	O
the	O
recruitment	O
of	O
MSM	O
participants	O
was	O
the	O
most	O
challenging	O
aspect	O
of	O
similar	O
behavioural	O
intervention	O
studies	O
.	O

To	O
overcome	O
these	O
barriers	O
we	O
are	O
employing	O
strategies	O
to	O
ensure	O
that	O
recruitment	O
and	O
retention	O
are	O
maximised	O
,	O
including	O
:	O
the	O
refinement	O
of	O
assessment	O
materials	O
with	O
the	O
MSM	O
community	O
;	O
the	O
use	O
of	O
a	O
telephone	O
-	O
based	O
intervention	O
to	O
overcome	O
geographic	O
boundaries	O
,	O
time	O
constraints	O
and	O
fear	O
of	O
public	O
exposure	O
as	O
an	O
MSM	O
;	O
the	O
recruitment	O
of	O
individuals	O
seeking	O
PEP	O
rather	O
than	O
the	O
recruitment	O
of	O
high	O
risk	O
individuals	O
from	O
the	O
community	O
.	O

This	O
study	O
will	O
identify	O
whether	O
it	O
is	O
appropriate	O
and	O
cost	O
-	O
effective	O
to	O
intervene	O
using	O
a	O
tailored	O
intervention	O
of	O
one	O
-	O
to	O
-	O
one	O
telephone	O
calls	O
with	O
MSM	O
prescribed	O
the	O
prophylactic	O
treatment	O
regimen	O
after	O
potential	O
sexual	O
exposure	O
to	O
HIV	B-OG
.	O

If	O
the	O
intervention	O
is	O
effective	O
,	O
further	O
work	O
will	O
be	O
needed	O
on	O
training	O
staff	O
to	O
deliver	O
the	O
intervention	O
competently	O
.	O

Endnotes	O

1	O
Maximum	O
of	O
2	O
repeat	O
copies	O
and	O
1	O
text	O
/	O
call	O
/	O
email	O
if	O
consented	O
by	O
patient	O
.	O

2	O
Incidence	O
data	O
on	O
rectal	B-DS
gonorrhoea	I-DS
and	O
Chlamydia	B-OG
will	O
be	O
collected	O
as	O
this	O
is	O
directly	O
related	O
to	O
the	O
risky	O
sexual	O
behaviour	O
that	O
we	O
are	O
assessing	O
in	O
this	O
trial	O
i	O
.	O
e	O
.	O
directly	O
related	O
to	O
condom	O
use	O
.	O

Competing	O
interests	O

The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O

CL	O
,	O
MF	O
,	O
CA	O
,	O
HS	O
,	O
AP	O
,	O
PB	O
,	O
AM	O
contributed	O
to	O
the	O
design	O
of	O
the	O
study	O
and	O
co	O
-	O
authored	O
this	O
article	O
.	O

All	O
authors	O
have	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Pre	O
-	O
publication	O
history	O

The	O
pre	O
-	O
publication	O
history	O
for	O
this	O
paper	O
can	O
be	O
accessed	O
here	O
:	O

http	O
://	O
www	O
.	O
biomedcentral	O
.	O
com	O
/	O
1471	O
-	O
2334	O
/	O
12	O
/	O
70	O
/	O
prepub	O

